Loading...
XBRUIBAB
Market cap405mUSD
Dec 20, Last price  
13.30EUR
1D
1.53%
1Q
-1.63%
Jan 2017
-68.06%
Name

Ion Beam Applications SA

Chart & Performance

D1W1MN
XBRU:IBAB chart
P/E
—
P/S
0.91
EPS
—
Div Yield, %
1.58%
Shrs. gr., 5y
-0.13%
Rev. gr., 5y
10.74%
Revenues
429m
+18.67%
188,879,000136,099,000170,257,000213,849,000332,607,000332,607,000387,591,000237,694,000221,106,000212,512,000220,577,000270,357,000328,774,000236,485,000257,406,999282,552,000311,955,000312,964,000361,270,000428,717,000
Net income
-9m
L
6,684,0003,048,00030,007,00013,846,0005,329,0005,329,0006,643,000-84,128,000-5,800,000-4,098,00024,294,00061,189,00024,440,000-41,658,000-4,401,0007,610,00031,921,0003,879,0006,057,000-9,110,000
CFO
-20m
L
40,044,000901,00013,652,00018,034,00011,916,00011,916,00031,412,00038,268,000-30,736,0006,763,00014,969,00045,394,000-17,018,000-44,641,000-18,521,00045,893,00098,254,00085,010,00020,897,000-19,769,000
Dividend
Jun 27, 20240.17 EUR/sh
Earnings
Mar 19, 2025

Profile

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
URL
https://iba-worldwide.com
IPO date
Jun 13, 1998
Employees
2,000
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
428,717
18.67%
361,270
15.44%
312,964
0.32%
Cost of revenue
422,300
350,220
298,454
Unusual Expense (Income)
NOPBT
6,417
11,050
14,510
NOPBT Margin
1.50%
3.06%
4.64%
Operating Taxes
8,795
(6,487)
4,376
Tax Rate
137.06%
30.16%
NOPAT
(2,378)
17,537
10,134
Net income
(9,110)
-250.40%
6,057
56.15%
3,879
-87.85%
Dividends
(6,121)
(5,579)
(5,785)
Dividend yield
1.82%
1.19%
1.26%
Proceeds from repurchase of equity
115
(4,984)
(10,250)
BB yield
-0.03%
1.06%
2.23%
Debt
Debt current
12,573
9,409
15,096
Long-term debt
57,010
31,458
53,880
Deferred revenue
536
20,811
23,943
Other long-term liabilities
8,013
12,173
14,418
Net debt
(77,362)
(149,193)
(168,353)
Cash flow
Cash from operating activities
(19,769)
20,897
85,010
CAPEX
(5,265)
(7,329)
(5,029)
Cash from investing activities
(13,324)
(19,135)
(8,025)
Cash from financing activities
(14,384)
(40,661)
(34,078)
FCF
(5,775)
20,116
47,860
Balance
Cash
109,615
167,986
200,652
Long term investments
37,330
22,074
36,677
Excess cash
125,509
171,996
221,681
Stockholders' equity
80,947
90,801
95,673
Invested Capital
76,267
76,726
111,541
ROIC
18.63%
7.86%
ROCE
4.07%
6.57%
7.00%
EV
Common stock shares outstanding
29,127
30,175
30,155
Price
11.54
-25.84%
15.56
2.10%
15.24
24.92%
Market cap
336,121
-28.41%
469,529
2.17%
459,568
26.78%
EV
258,759
320,336
291,215
EBITDA
17,938
21,761
24,403
EV/EBITDA
14.43
14.72
11.93
Interest
2,051
2,851
3,718
Interest/NOPBT
31.96%
25.80%
25.62%